HIGHLIGHTS
- who: Thomas Rodier and collaborators from the Biologie du Mu00e9dicament-Toxicologie, Hu00f4pital, Paris, France School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland have published the article: Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer, in the Journal: Pharmaceutics 2022, x FOR PEER REVIEW Pharmaceutics 2022, 14,14, 1844 of 10/Oct/2020
- what: The aim of this study was to evaluate the exposure-response relationship for toxicity and efficacy of osimertinib in unselected patients with advanced EGFR-mutant NSCLC. In the present study, baseline serum CRP level was . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.